Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas

American Journal of Clinical Pathology

Volumn 123, Issue 4, 2005, Pages 541-546

  Lal, Priti ^a   Tan, Lee K ^a   Chen, Beiyun ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast carcinoma; c erbB 2; Estrogen receptor; FISH; Fluorescence in situ hybridization; HER 2 neu; Histology; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 15744401575     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/YMJ3A83TB39MRUT9     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. Allegra JC, Lippman ME, Thompson EB, et al. Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer. 1980;16:323-331.
3. Tsuda H, Tsugane S, Fukutomi T, et al. Prognostic factors for recurrent breast cancer, univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene. Jpn J Clin Oncol. 1992;22:244-249.
4. Horita K, Yamaguchi A, Hirose K, et al. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem. 2001;45:73-84.
5. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001;10:139-152.
6. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
7. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001;27:137-142.
8. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers: a review. Gene. 1995;159:19-27.
9. Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast; clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77:113-120.
10. Zafrani B, Aubriot MH, Mouret E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology. 2000;37:536-545.
11. Campbell FC, Blamey RW, Elston CW, et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1981;2:1317-1319.
12. Heuson JC, Longeval E, Mattheiem WH, et al. Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer. 1977;39:1971-1977.
13. Ferrero-Pous M, Trassard M, Le Doussal V, et al. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol. 2001;9:267-275.
14. Taucher P, Rudas M, Mader RM, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 2003;98:2547-2553.
15. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:13-59. World Health Organization Classification of Tumours.
16. Seidman AD, Fornier M, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER-2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
18. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.
19. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer. 1990;65:1794-1800.
20. Hoff ER, Tubbs RR, Myles JL, et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002;117:916-921.
21. Porter PL, Garcia R, Moe R, et al. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer. 1991;68:331-334.